Has the U.K. Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 3.8x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 26 Jun 2026	UK£3.3b	UK£893.7m	-UK£153,977,054.90	18.5x	-21.5x	3.7x
Sun, 24 May 2026	UK£3.5b	UK£892.4m	-UK£149,274,968.20	19.3x	-23.7x	4x
Tue, 21 Apr 2026	UK£3.3b	UK£889.7m	UK£11.4m	12.6x	287.1x	3.7x
Thu, 19 Mar 2026	UK£3.3b	UK£875.5m	-UK£4,125,117.77	8.8x	-792.1x	3.7x
Sat, 14 Feb 2026	UK£3.8b	UK£876.0m	-UK£28,365,510.76	10.1x	-132.6x	4.3x
Mon, 12 Jan 2026	UK£3.4b	UK£876.1m	-UK£28,301,626.82	10.5x	-118.8x	3.8x
Wed, 10 Dec 2025	UK£3.2b	UK£897.0m	-UK£29,128,634.75	10.3x	-111x	3.6x
Fri, 07 Nov 2025	UK£3.1b	UK£886.7m	-UK£42,937,277.77	11.2x	-73.3x	3.6x
Sun, 05 Oct 2025	UK£3.2b	UK£878.6m	-UK£41,075,559.25	16.2x	-79.1x	3.7x
Tue, 02 Sep 2025	UK£3.4b	UK£855.6m	-UK£107,581,632.29	12.1x	-32x	4x
Thu, 31 Jul 2025	UK£3.1b	UK£855.0m	-UK£102,661,269.51	13.2x	-30.6x	3.7x
Sat, 28 Jun 2025	UK£2.6b	UK£854.5m	-UK£104,252,166.04	13x	-24.5x	3x
Mon, 26 May 2025	UK£2.4b	UK£879.0m	-UK£92,157,633.95	13.8x	-26.2x	2.7x
Wed, 23 Apr 2025	UK£2.1b	UK£876.5m	-UK£170,948,298.30	16.6x	-12.4x	2.4x
Fri, 21 Mar 2025	UK£2.4b	UK£844.0m	-UK£277,143,424.75	16.9x	-8.7x	2.9x
Sun, 16 Feb 2025	UK£2.7b	UK£841.7m	-UK£294,450,173.91	86.9x	-9.2x	3.2x
Tue, 14 Jan 2025	UK£2.5b	UK£842.8m	-UK£297,311,300.79	71.6x	-8.4x	3x
Thu, 12 Dec 2024	UK£2.7b	UK£841.3m	-UK£293,157,899.89	79.9x	-9.1x	3.2x
Sat, 09 Nov 2024	UK£2.8b	UK£840.3m	-UK£292,669,951.14	89.3x	-9.4x	3.3x
Mon, 07 Oct 2024	UK£2.9b	UK£840.1m	-UK£295,236,161.83	97.5x	-9.9x	3.5x
Wed, 04 Sep 2024	UK£2.8b	UK£834.9m	-UK£289,017,668.26	30.6x	-9.8x	3.4x
Fri, 02 Aug 2024	UK£2.7b	UK£838.3m	-UK£257,806,790.96	31.2x	-10.5x	3.2x
Sun, 30 Jun 2024	UK£2.5b	UK£835.8m	-UK£261,129,045.99	29.4x	-9.5x	3x
Tue, 28 May 2024	UK£3.0b	UK£836.7m	-UK£287,424,883.92	31.1x	-10.4x	3.6x
Thu, 25 Apr 2024	UK£3.1b	UK£902.8m	-UK£201,599,900.90	30x	-15.1x	3.4x
Sat, 23 Mar 2024	UK£3.1b	UK£900.2m	-UK£203,946,855.16	34.5x	-15.4x	3.5x
Mon, 19 Feb 2024	UK£3.1b	UK£913.4m	-UK£198,085,887.55	31.2x	-15.8x	3.4x
Wed, 17 Jan 2024	UK£6.4b	UK£1.3b	-UK£245,592,050.00	38.3x	-26x	5x
Fri, 15 Dec 2023	UK£6.2b	UK£1.3b	-UK£245,035,687.00	37.1x	-25.1x	4.9x
Sun, 12 Nov 2023	UK£6.3b	UK£1.3b	-UK£243,279,195.00	37.1x	-25.9x	5x
Tue, 10 Oct 2023	UK£6.5b	UK£1.3b	-UK£250,845,593.00	37.6x	-26.1x	5.1x
Thu, 07 Sep 2023	UK£6.6b	UK£1.3b	-UK£205,725,417.00	23.6x	-32x	5.2x
Sat, 05 Aug 2023	UK£6.9b	UK£1.3b	-UK£209,009,826.00	23.6x	-32.8x	5.4x
Mon, 03 Jul 2023	UK£6.7b	UK£1.3b	-UK£209,123,429.00	23.9x	-31.9x	5.3x


GB Market	0.80%
Healthcare	5.40%
Biotech	0.21%
Biotech	0.21%

Company	Last Price	7D	1Y	Valuation
OXB Oxford Biomedica	UK£6.34	4.4% +UK£32.6m	98.1%	PS4.5x
AVCT Avacta Group	UK£0.76	3.4% +UK£11.7m	149.2%	PS3150.3x
PRTC PureTech Health	UK£1.32	1.2% +UK£3.9m	2.5%	PS90.8x
APTA Aptamer Group	UK£0.0055	15.8% +UK£2.6m	61.8%	PS13.8x
SBTX SkinBioTherapeutics	UK£0.11	2.3% +UK£647.9k	-32.3%	PS5.6x

Announcement • Jun 22

Solvonis Therapeutics Announces Positive Bridging Data Supporting Planned U.S. 505(b)(2) Pathway Towards Phase 2b Clinical Trial of SVN-002

Solvonis Therapeutics plc announced positive pharmacokinetic (PK) data from the preclinical bridging study for its SVN-002 development programme. SVN-002 is Solvonis' proprietary esketamine oral thin-film (OTF) formulation being developed for moderate-to-severe Alcohol Use Disorder (AUD) in the United States. It is designed for supervised, clinic-administered sublingual-buccal dosing. The programme also incorporates a structured alcohol education component, intended for future remote digital access by patients. The programme is being advanced under a planned U.S. Food and Drug Administration (FDA) 505(b)(2) regulatory pathway referencing the FDA-approved intranasal esketamine product, Spravato®. The nonclinical study was designed to assess whether the intended combined sublingual-buccal administration of SVN-002 could generate systemic esketamine exposure supportive of a scientific bridge to the approved intranasal esketamine reference product. At the same nominal dose level, combined sublingual-buccal administration of SVN-002 produced rapid systemic exposure to parent esketamine. Exposure levels for parent esketamine and the key measured metabolites, noresketamine and hydroxynoresketamine, were within the range observed for the intranasal esketamine comparator arm, providing important translational support for the planned scientific bridge. At the December 2024 Type B pre-IND meeting held with the FDA by Awakn Life Sciences, prior to the asset's acquisition by Solvonis, FDA identified systemic exposure to esketamine and relevant metabolite exposure as key considerations for the initial Investigational New Drug (IND) package. Solvonis believes these newly generated data provide important translational support in relation to the FDA-identified exposure considerations and strengthen the planned initial IND package for SVN-002. Following these positive results, Solvonis will seek further FDA feedback on the scope and scale of the remaining nonclinical toxicology work required for the initial IND submission. Subject to FDA feedback and successful completion of this targeted toxicology package, Solvonis plans to submit an IND to support the initiation of a Phase 2b clinical trial of SVN-002 in patients with moderate-to-severe AUD in the United States. AUD represents a major and underserved U.S. market opportunity characterised by limited pharmacological innovation. According to the 2024 U.S. National Survey on Drug Use and Health, approximately 27,900,000 people aged 12 and older in the U.S. had Alcohol Use Disorder in the past year. Solvonis estimates that approximately 15,000,000 U.S. adults fall within the programme's target moderate-to-severe AUD population. Spravato® provides a relevant commercial reference point for supervised, clinic-administered esketamine treatment models. Johnson & Johnson reported worldwide Spravato® sales of approximately USD 1,700 million in 2025 for depression-related indications. Solvonis estimates that SVN-002's target U.S. moderate-to-severe AUD population is approximately five times larger than the estimated U.S. treatment-resistant depression comparator population of approximately 2,800,000 people. The planned 505(b)(2) pathway is central to the capital efficiency of the SVN-002 development strategy. A successful 505(b)(2) route may allow Solvonis to rely, in part, on the FDA's prior findings of safety and/or effectiveness for the approved intranasal esketamine reference product, provided a suitable scientific bridge is established. Solvonis intends to build the SVN-002 package using existing third-party preclinical data, in-licensed Phase 1 clinical data, and targeted SVN-002 bridging and toxicology studies, rather than duplicating a full conventional de novo development package. The Company believes this approach has the potential to reduce development expenditure and support a more capital-efficient route towards Phase 2b. The pharmacokinetic profile observed in this study is very encouraging. Combined sublingual-buccal administration produced rapid systemic exposure to parent esketamine and supports the core rationale for SVN-002 as a transmucosal thin-film product. These results provide important translational evidence for the planned U.S. regulatory pathway and support SVN-002's continued development as a supervised, clinic-administered treatment candidate for AUD.

Announcement • Jun 16

Cizzle Biotechnology Holdings Plc CIZ1B Biomarker Test Approval For Clinical Use In USA

Cizzle Biotechnology Holdings Plc announced the successful laboratory accreditation of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. Working closely with the Company's North American licensing partner Cizzle Bio Inc, the test is now approved for use under Clinical Laboratory Improvement Amendments accreditation at OmniHealth Diagnostics, a CLIA-certified, COLA-accredited clinical laboratory based in Dallas, Texas. CLIA approval is regulated by the Centers for Medicare & Medicaid Services and signifies that a laboratory's testing processes and assays meet US federal standards for timely clinical accuracy, reliability, and patient safety and will now enable the test to be made available to licensed U.S. healthcare providers. CLIA compliance is also mandatory for a laboratory to receive Medicare and Medicaid reimbursements. The CIZ1B biomarker test is a novel, ELISA-based immunoassay that detects a specific protein variant associated with early-stage lung cancer through a simple blood draw. The test is designed to complement LDCT screening and other standard-of-care diagnostic approaches, helping clinicians assess cancer risk, clarify indeterminate findings, and make more informed clinical decisions. Unlike multi-cancer early detection tests that rely on detecting circulating tumor DNA bearing mutation or methylation signals, CIZ1B is designed to detect a stable tumor-associated protein biomarker linked to lung cancer at its earliest stage. This distinct biomarker approach offers important advantages in identifying disease when intervention has the greatest potential to improve outcomes. CIZ1B is offered as a laboratory developed test and is performed exclusively within CLIA-certified laboratory environments, ensuring rigorous quality oversight, analytical control, and compliance with applicable regulatory standards. The validation at OmniHealth confirms the test's analytical performance and operational readiness within a U.S. clinical laboratory environment, supporting scalability, reproducibility, and integration into routine diagnostic workflows. This provides an accredited base to roll the test out across the USA and establishes a strong foundation for growth in other global and home markets. The CIZ1B biomarker test is built on foundational research into cancer origins, and the CIZ1 protein's role in epigenetic stability, led by Professor Dawn Coverley at the University of York. Her work led to the discovery of the CIZ1B protein variant and its strong association with lung cancer, and the development of molecular tools that can measure CIZ1B with high sensitivity in patients with early-stage lung cancer. With CLIA accreditation, clinicians and patients will now have access to a scalable test that can help with the detection of lung cancer in its early stages and improve a patient's chance of survival. Achieving CLIA accreditation is necessarily a complex and challenging task and was made possible through working closely with Cizzle's North American Licensing partner, BIO, and its clinical laboratory partner OmniHealth, bringing together the necessary research, development, regulatory, clinical and commercial expertise to deliver a vision to transform lung cancer survival through accurate, low cost, non-invasive early detection at scale. As part of the Company's global licensing strategy, there has been a first focus on the world's largest market in North America to launch its first commercial test. The goal is now to continue to work with the Company's partners to deliver early adoption and scale up. Having established a regulatory approved route to market in the USA, the Company is now also exploring new commercial relationships in the UK, elsewhere in Europe and Asia. This strategy aims to continue to deliver shareholder value through licensing-based royalty payments and potential benefits arising from equity participation in the partner companies where possible.

U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Palatin Technologies, Inc., Annual General Meeting, Jul 28, 2026

OXB: Fast-Track Viral Vector Services Will Support Higher Quality Business Perception

New minor risk - Share price stability

GNS: Margin Discipline And New Bank Coverage Will Support Medium Term Upside

Solvonis Therapeutics Announces Positive Bridging Data Supporting Planned U.S. 505(b)(2) Pathway Towards Phase 2b Clinical Trial of SVN-002

Hub And Spoke Model Will Unlock Multiple Royalty Streams Over The Long Term

Investor sentiment improves as stock rises 18%

Cizzle Biotechnology Holdings Plc CIZ1B Biomarker Test Approval For Clinical Use In USA

First half 2026 earnings released: UK£0.003 loss per share (vs UK£0.005 loss in 1H 2025)

Hemogenyx Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2026

Genflow Biosciences plc, Annual General Meeting, Jun 29, 2026

New major risk - Revenue and earnings growth

ProBiotix Health Plc, Annual General Meeting, Jun 23, 2026

OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026

New minor risk - Share price stability

New major risk - Shareholder dilution